PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.
"There is a huge need for safe and effective drugs for people suffering from neuropathic pain. Our drug candidate PN6047 has a novel mode of action that avoids the unwanted side effects of current treatments. I will be sharing the latest progress in the ongoing Phase I clinical trial and discuss the design of our upcoming Phase IIa studies planned for next year," says Per von Mentzer, CEO at PharmNovo.
Per von Mentzer is presenting on 4 May, at 10:45 at Showcase Biotech.
The LSX World Congress is Europe's leading partnering, strategy, and investment event for life science and executive leaders. To learn more about LSX and explore the agenda for the world congress, visit: https://lnkd.in/eZUDkZSv
PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.
"There is a huge need for safe and effective drugs for people suffering from neuropathic pain. Our drug candidate PN6047 has a novel mode of action that avoids the unwanted side effects of current treatments. I will be sharing the latest progress in the ongoing Phase I clinical trial and discuss the design of our upcoming Phase IIa studies planned for next year," says Per von Mentzer, CEO at PharmNovo.
Per von Mentzer is presenting on 4 May, at 10:45 at Showcase Biotech.
The LSX World Congress is Europe's leading partnering, strategy, and investment event for life science and executive leaders. To learn more about LSX and explore the agenda for the world congress, visit: https://lnkd.in/eZUDkZSv
PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.
Read moreOn May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.
Read moreThe final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read moreBengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more